266 related articles for article (PubMed ID: 37602328)
1. The role of p53 in anti-tumor immunity and response to immunotherapy.
Carlsen L; Zhang S; Tian X; De La Cruz A; George A; Arnoff TE; El-Deiry WS
Front Mol Biosci; 2023; 10():1148389. PubMed ID: 37602328
[TBL] [Abstract][Full Text] [Related]
2. Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" Melanoma.
Dinavahi SS; Chen YC; Punnath K; Berg A; Herlyn M; Foroutan M; Huntington ND; Robertson GP
Cancer Immunol Res; 2022 Jun; 10(6):757-769. PubMed ID: 35439317
[TBL] [Abstract][Full Text] [Related]
3. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
5. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
Cui Y; Guo G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
[TBL] [Abstract][Full Text] [Related]
7. Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.
Guo G; Yu M; Xiao W; Celis E; Cui Y
Cancer Res; 2017 May; 77(9):2292-2305. PubMed ID: 28280037
[TBL] [Abstract][Full Text] [Related]
8. A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development.
Shi D; Jiang P
Front Cell Dev Biol; 2021; 9():762651. PubMed ID: 34733856
[TBL] [Abstract][Full Text] [Related]
9. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
10. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH
Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175
[TBL] [Abstract][Full Text] [Related]
11. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.
Mkrtichyan M; Chong N; Abu Eid R; Wallecha A; Singh R; Rothman J; Khleif SN
J Immunother Cancer; 2013; 1():15. PubMed ID: 24829751
[TBL] [Abstract][Full Text] [Related]
13. Mathematical modeling for the combination treatment of IFN-γ and anti-PD-1 in cancer immunotherapy.
Liao KL; Watt KD
Math Biosci; 2022 Nov; 353():108911. PubMed ID: 36150452
[TBL] [Abstract][Full Text] [Related]
14. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
15. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
16. Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe.
Asl ER; Rostamzadeh D; Duijf PHG; Mafi S; Mansoori B; Barati S; Cho WC; Mansoori B
Life Sci; 2023 Feb; 315():121361. PubMed ID: 36608871
[TBL] [Abstract][Full Text] [Related]
17. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
[TBL] [Abstract][Full Text] [Related]
18. Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents.
Carlsen L; El-Deiry WS
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769259
[TBL] [Abstract][Full Text] [Related]
19. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
[TBL] [Abstract][Full Text] [Related]
20. Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer.
Zhu S; Wu Q; Zhang B; Wei H; Li B; Shi W; Fang M; Zhu S; Wang L; Lang Zhou Y; Dong Y
Int Immunopharmacol; 2020 Oct; 87():106757. PubMed ID: 32769067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
